Epidemiology and treatment of depression in patients with chronic medical illness by J. Katon, Wayne.
here is increasing recognition that patients with
major depression and bipolar disorder are dying pre-
maturely due to medical illnesses. Evidence suggests that
patients with depression die 5 to 10 years earlier and
those with bipolar illness die 10 to 20 years earlier than
patients without these psychiatric disorders.
1,2 They die
from medical disorders such as vascular disease, diabetes,
chronic obstructive pulmonary disease (COPD)/asthma
and cancer, which account for most mortality in the gen-
eral population. However, patients with depression and
other psychiatric illnesses often develop these illnesses
at an earlier age due to both maladaptive health risk
behaviors as well as the physiologic effects of their psy-
chiatric illnesses. There is also emerging evidence that
the distress, symptom burden, and functional impairment
and physiologic changes associated with chronic medical
disorders often worsen the course of affective illness.
3,4
This article will review the bidirectional relationship
between depression and chronic medical illness and the
association of depression with problems in the physician-
patient relationship, health risk behaviors, medical symp-
tom burden, functional impairment, adherence to self-
care regimens, medical complications, and mortality. The
maladaptive psychophysiologic effects of depression on
hypothalamic-pituitary axis, autonomic nervous system,
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There is a bidirectional relationship between depression
and chronic medical disorders. The adverse health risk
behaviors and psychobiological changes associated with
depression increase the risk for chronic medical disorders,
and biological changes and complications associated with
chronic medical disorders may precipitate depressive
episodes. Comorbid depression is associated with
increased medical symptom burden, functional impair-
ment, medical costs, poor adherence to self-care regi-
mens, and increased risk of morbidity and mortality in
patients with chronic medical disorders. Depression may
worsen the course of medical disorders because of its
effect on proinflammatory factors, hypothalamic-pitu-
itary axis, autonomic nervous system, and metabolic fac-
tors, in addition to being associated with a higher risk of
obesity, sedentary lifestyle, smoking, and poor adherence
to medical regimens. Both evidence-based psychothera-
pies and antidepressant medication are efficacious treat-
ments for depression. Collaborative depression care has
been shown to be an effective way to deliver these treat-
ments to large primary care populations with depression
and chronic medical illness.   
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Studies that have tested whether evidence-based depres-
sion psychotherapies and pharmacological treatments
are efficacious in patients with comorbid depression and
chronic medical illness will be described. The evidence
in this review will focus on the complex interaction
between depression and two of the most common med-
ical disorders: diabetes and cardiovascular disease.
Epidemiology of depression and
chronic medical illness
Patients with chronic medical illnesses have been found
to have two- to threefold higher rates of major depres-
sion compared with age- and gender-matched primary
care patients.
5-7 Rates of depression in primary care
patients are between 5% and 10%,
8 whereas prevalence
rates of depression in patients with diabetes and coro-
nary heart disease (CHD) have been estimated to be
12% to 18%
5 and 15% to 23%
6,7 respectively.
Patten and colleagues found in a large, prospective
Canadian community-based study that there was an
increased risk of development of major depression in
subjects with chronic medical disorders compared with
those without such disorders.
9 A total of 4% of those
with one or more medical conditions versus 2.8% of
those without medical conditions developed major
depression over a 2-year period.
9 Wells and colleagues
in the Epidemiologic Catchment Area Study found that
respondents suffering from one or more of eight chronic
medical conditions had a 41% increase in the risk of
having any recent psychiatric disorder (depression, anx-
iety, or substance abuse).
10 Von Korff and colleagues
have shown that childhood adversity and depression
occurring in adolescence to early adulthood were inde-
pendent risk factors for development in adulthood of a
range of medical disorders, including diabetes, coronary
heart disease, asthma, osteoarthritis, epilepsy, and hyper-
tension.
11
Studies have suggested that the relationship between
depression and diabetes and/or heart disease is bidirec-
tional. A recent meta-analysis of 13 studies that included
6916 subjects examined whether depression predicted
subsequent development of diabetes.
12 This systematic
review found that the pooled relative risk (RR) of
depression predicting diabetes was 1.60 (95% CI 1.37,
1.88).
12 This meta-analysis also found 7 studies repre-
senting 6414 subjects that examined whether type 2 dia-
betes increased the subsequent risk of depression. There
was modest evidence to support the hypotheses that dia-
betes was a risk factor for subsequent depression [RR =
1.15 (95% CI 1.02, 1.30)].
12 A recent 5-year prospective
study examined factors associated with major depression
at 5-year follow-up in approximately 3000 patients with
diabetes. Baseline minor and major depression, the num-
ber of diabetes symptoms, and having one or more car-
diac procedures during the 5-year follow-up (OR=1.92,
95% CI 1.10, 3.35) were independent predictors of major
depression at this 5-year time-point.
3
A systematic review found 8 studies that examined the
risk of depression for subsequent onset of myocardial
infarction. Clinically diagnosed major depressive disor-
der was identified as an important risk factor for subse-
quent development of cardiovascular disease (CVD, RR
=1.60 [95% CI 1.34, 1.92]).
13 Depression following
myocardial infarction is also very common, occurring in
up to 25% of patients.
6,7 Recent data suggests that about
half of these patients who developed depression post-MI
had recurrent depressive episodes, and half had their
first depressive episode post-MI.
7 Those with a first
episode post-MI had more severe ventricular damage
and had shorter duration of depression. 
Conceptual model
Figure 1 describes a conceptual model for the complex
interactions between depression and chronic medical ill-
ness.
14 Both genetic predisposition and exposure to child-
hood adversity, such as physical or sexual abuse, have
been shown to be vulnerability factors for development
of depression.
15 Stressful life events are more likely to
precipitate initial episodes of depression in patients with
one or more of these vulnerability factors.
16 In addition,
exposure to childhood adversity may lead to maladaptive
attachment patterns which may result in lack of social
support and problems with interpersonal relationships.
This lack of support can also precipitate or worsen
depressive episodes.
17,18 Maladaptive attachment may also
affect the quality of the doctor-patient relationship—as
reviewed below. Both childhood adversity and develop-
ment of depression in adolescent or early adult years are
also associated with adverse health behaviors such as
poor diet, obesity, sedentary lifestyle, and smoking , which
increase the risk of development of diabetes and
CVD.
11,19,20These behaviors add to biological factors that
have been shown to be associated with both depression
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increased proinflammatory factors that may lead to early
development of chronic medical disorders such as dia-
betes or CHD. Once people develop chronic medical ill-
ness, comorbid depression is associated with increased
symptom burden
21 and additive functional impairment.
22
The aversive symptoms and functional impairments asso-
ciated with chronic medical illness may also precipitate
or worsen major depression. Comorbid depression may
also worsen the course of chronic medical illness because
of its adverse effect on adherence to self-care regimens
(diet, exercise, cessation of smoking, taking medications
as prescribed)
23 and direct pathophysiological effects on
inflammatory and metabolic factors, hypothalamic pitu-
itary axis and autonomic nervous system.
24The effects of
these risk factors may be buffered by social and envi-
ronmental support and access to quality mental health
and physical health care. 
Patient-physician relationship
Managing chronic illness often requires close collabora-
tion between patients and physicians as well as patients
and family members. Primary care physicians rate
patients with depression as more difficult to evaluate
and treat compared with patients without affective dis-
orders.
25 Patients with depression make approximately
twice as many health care visits—often for vague physi-
cal symptoms—but also miss more visits.
26 These visits
by depressed patients take longer for primary care
physicians often because of multiple competing demands
such as discussion of life stressors, problems with non-
adherence to self-care of chronic medical conditions
(diet, exercise, taking medications as prescribed), acute
medical complaints such as headaches or abdominal
pain, and poor control of chronic medical illnesses.
27
Compared with nondepressed controls, patients with
depression are less satisfied with primary care physi-
cians
28 perhaps due to maladaptive attachment patterns
such as either fear of leaning on others (including physi-
cians) or anxious attachment.
29 These maladaptive
attachment patterns likely occur more often in patients
with depression due to higher rates of childhood adver-
sity.
17,18 Patients with depression may delay visits for
important medical problems or adhere poorly to med-
ical recommendations due to fears of becoming depen-
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Figure 1. Bidirectional interaction between depression and chronic medical disorders. 
Reproduced from ref 14: Katon WJ. Clinical and health services relationships between major depression, depressive symptoms, and general medical illness.
Biol Psychiatry. 2003;54:216-226. Copyright © Elsevier, 2003
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30 Ciechanowski and colleagues have
shown that patients with diabetes with fear of leaning on
others (ie, insecure attachment) have poorer adherence
to self care, miss more regularly scheduled visits,
26 and
have poorer disease control compared with patients with
diabetes with normal attachment styles.
30 Patients with
anxious attachment may be overly dependent on physi-
cians, leading to increased medical utilization for minor
somatic symptoms, multiple phone calls, and ensuing
physician frustration.
31
Recent studies have evaluated the effect of comorbid
depression in patients with chronic medical illness on
patient perception of physician communication. The
presence of comorbid depressive symptoms in patients
with diabetes has shown to be associated with patients
reporting poor communication, including: elicitation of
patient problems, concerns, and expectations, explana-
tions about their condition, and patient empowerment
and decision-making.
32 In patients with CHD, each addi-
tional standard deviation increase in depression symp-
toms was found to be associated with 50% greater odds
of patients reporting poor explanations about their med-
ical condition, and 30% greater odds of patients report-
ing physicians responding poorly to their preferences for
treatment.
33
Adherence to self-care
Caring for chronic illness takes patient planning, time,
and motivation. Depression may impair self-care of
chronic illness by adversely effecting memory, energy,
and executive function.
14 Moreover, the sense of help-
lessness and hopelessness associated with depression
may decrease motivation to care for chronic illness. A
systematic review by Dimatteo and colleagues found
that comorbid depression in patients with chronic med-
ical illness decreased adherence to self-care regimens by
threefold.
34
Studies in patients with diabetes have shown that
depression adversely effects adherence to diet, exercise
regimens, cessation of smoking, and taking the three key
diabetes control medications as prescribed; oral hypo-
glycemics, antihypertensives, and lipid control medica-
tions.
23 On the other hand, comorbid depression in
patients with diabetes did not affect the quality of the
types of care that physicians have more control over,
such as annual retinal or foot exams, ordering HbA1C
levels at least twice a year,
23 or increasing intensity of
pharmacological care based on poor control of HbA1C,
LDL cholesterol, and blood pressure.
35
In patients hospitalized after an acute myocardial infarc-
tion (MI), those with at least mild-to-moderate depres-
sive symptoms were found to have lower adherence 4
months later to a low-fat diet, regular exercise, reducing
stress, and increasing social support.
36Those with comor-
bid major depression or dysthymia and CHD compared
with those with CHD alone also reported taking med-
ications as prescribed less often than those without
comorbid affective illnesses.
36 In the Heart and Soul
Study, which followed a large cohort of patients with
CHD over time, twice as many depressed patients as
nondepressed patients reported both forgetting to take
their medications as prescribed and deciding to skip
their medications.
37 Several studies have also shown that
patients with depression and CHD versus those with
CHD alone are less likely to adhere to taking daily low-
dose aspirin.
38,39 Patients with comorbid depression and
CHD compared with those with CHD alone have also
been found to be more likely to drop out of cardiac exer-
cise rehabilitation programs.
40
Medical utilization and costs
Studies have shown that patients with major depression
tend to be high utilizers of general medical services. In
the Epidemiologic Catchment Area Study, Simon and
colleagues showed that males with depression had a 50%
greater risk and females with depression had an over
threefold greater risk of being high utilizers of general
medical services (defined as >6 visits in 6 months) com-
pared with controls without psychiatric illness.
41 Katon
and colleagues found that in a large primary care popu-
lation, patients in the highest 10% of utilization of pri-
mary care services used 29% of primary care visits, 52%
of specialty visits, 40% of hospital days, and 26% of pre-
scriptions.
42 Approximately 50% of the over 1000 high
utilizers screened were psychologically distressed (based
on SCL-90 depression, anxiety, or somatization scales)
and two thirds of these distressed patients met DSM-IV
criteria for recurrent major depression and 40% for dys-
thymia based on structured psychiatric interview.
42Two
thirds also had one or more chronic medical illnesses. 
Primary care patients with major depression have been
found to have 50% to 100% greater medical costs than
nondepressed controls after controlling for sociodemo-
graphic factors and severity of medical illness.
43,44 Patients
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to have 50%
45 greater total medical costs, and those with
comorbid depression and congestive heart failure have
been found to have 30%
46 greater total medical costs
after controlling for sociodemographic factors and sever-
ity of medical illness. Moreover, the mean costs of
patients with diabetes or heart disease are up to fourfold
higher than age-matched controls without these illnesses,
which places these patients in an extremely high cost
bracket. For instance, research at a large health main-
tenance organization has shown that a middle-aged
adult with minimal medical illness has a mean of about
$1500 annual health care costs, a middle-aged depressed
patient with minimal medical illness has a mean of
approximately $3000 annual health care costs, a middle-
aged adult with diabetes has about $6000 in mean
annual health care costs, and a middle-aged adult with
comorbid depression and diabetes has about $9000 in
annual health care costs.
45,47
The increase in total medical costs is not explained by an
increase in mental health utilization, which has been
found to explain only about 10% of the increase in med-
ical costs.
43,44,47 Multiple studies have shown that depres-
sion is associated with increased costs in every cost com-
ponent that is measured including primary care,
pharmacy, medical specialty, emergency or urgent care,
laboratory, inpatient medical, inpatient psychiatric, and
outpatient mental health. 
Two studies that evaluated the cost–effectiveness of col-
laborative depression care interventions in patients with
comorbid major depression and/or dysthymia and dia-
betes have shown that the intervention was not only asso-
ciated with improved quality of depression care and
depression outcomes, but that the increased mental
health costs associated with the interventions were offset
by greater savings in medical costs, especially at year 2.
48,49
A recent study extended the follow-up of patients in one
of these intervention studies of patients with depression
and diabetes for 5 years.
50The same savings in total med-
ical costs that were found in intervention versus usual
care patients over the first 2 years continued during years
3 to 5.
50When compared with usual care, the collabora-
tive care intervention was associated with trends for a
decrease in every cost component (ie, primary care, med-
ical specialty, pharmacy, laboratory, and inpatient costs).
48-50
Thus, effective depression treatment is associated with
decreases in many different types of health care costs. 
Medical symptom perception
Patients with depression have been found to have two-
to threefold more medical symptoms on a medical
review of symptoms compared with controls without
depression, after controlling for sociodemographic fac-
tors and severity of medical illness.
51 Table I shows the
results of a study by Kroenke and colleagues in which
1000 primary care patients filled out the Patient Health
Questionnaire depression and anxiety scales (general-
ized anxiety disorder and panic disorder) and a 15-item
somatic symptom scale before they saw their primary
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No (%) with psychiatric disorder
No of symptoms No of patients DSM-IV anxiety disorder N(%) DSM-IV mood disorder N(%)  Any anxiety/DSM-IV 
depressive disorder (N%)
Physical (n=1000)
0-1 215 2 (1) 5 (2) 16 (7)
2-3 225 17 (7) 27 (12) 50 (22)
4-5 191 25 (13) 44 (23) 67 (35)
6-8 230 68 (30)  100 (44) 140 (61)
≥9 139 66 (48) 84 (60) 113 (81)
Somatoform (n=933)
0 654 68 (10) 107 (16) 162 (25)
1-2 143 42 (29) 60 (42) 74 (52)
3-5 87 35 (40)  40 (46) 77 (89)
≥6 49 27 (55) 34 (69) 46 (94) 
Table I. Number of physical symptoms and association with DSM-IV anxiety and depressive disorders. 
Reproduced from ref 52: Kroenke K, Spitzer RL, Williams JB, et al. Physical symptoms in primary care. Predictors of psychiatric disorders and functional impairment.
Arch Fam Med. 1994;3:774-779. Copyright © Americal Medical Association 1994
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52 Primary care physicians were then
asked to rate the patient’s somatic symptoms as poten-
tially due to a physical illness or unexplained (the
authors describe these latter symptoms as somatoform).
As seen in Table I, whether the physician describes the
patients' symptoms as due to a medical illness or as
unexplained or somatoform did not change the rela-
tionship to depressive and anxiety conditions.
52 Increased
somatic symptoms of either type were associated with a
higher likelihood that the patient suffered from a DSM-
IV depressive or anxiety disorder. 
Pain symptoms are particularly common in patients with
depression.
51 Longitudinal data suggest a bidirectional
association between pain and depression.
9,53 Community-
based studies have found that respondents with depres-
sion have a higher likelihood than nondepressed respon-
dents to develop an incident pain symptom.
53 Persistent
pain symptoms in community respondents without
depression are also associated with a higher likelihood
of developing subsequent depression.
9,53 Recent data
from the Health Care for Communities study have
shown that depression at baseline survey was one of the
strongest predictors of subsequent development of reg-
ular opiate use at a 5-year follow-up (presumably for
treatment of chronic pain).
54 Multifocal pain is especially
likely to be associated with depression and with opiate
use.
55
Many patients with chronic illness must learn to adapt
and habituate to chronic aversive symptoms, such as
pain or fatigue. When patients are not depressed, most
patients with chronic medical illness are able to suc-
cessfully adapt to their chronic aversive disease symp-
toms.
51 However, there is now extensive data to suggest
that having comorbid anxiety and depressive disorders
in patients with chronic medical illness interferes with
this adaptation process, and is associated with height-
ened awareness and focus on both symptoms of that
physical illness as well as physical symptoms associated
with other organ systems.
51
The lack of adaptation to aversive symptoms may be
explained by dysregulation of the endogenous pain mod-
ulatory system.
56,57The periaqueductal gray (PAG) is a
key anatomic structure in this modulatory system. The
PAG is an important source of endogenous opioids and
an anatomic relay station from limbic forebrain and mid-
brain structures to the brain stem. The amygdala, hypo-
thalamus, and frontal neocortex all send fibers to the
PAG, which, in turn, connects with relay stations in the
pons and medulla.
57 These relay stations contain sero-
tonergic neurons such as those in the rostral-ventrome-
dial medulla (RVM) as well as noradrenergic neurons
such as those in the dorsolateral pontine tegmentum
(DLPT).
58The RVM sends projections to the dorsal horn
of the spinal cord directly, whereas the DLPT affects the
dorsal horn neurons indirectly by its projection to the
RVM as well as by having direct connections to the dor-
sal horn. The RVM has “on cells,” which facilitate trans-
mission of spinal nociception to the brain, and “off cells”
that inhibit this transmission.
56
The above on and off cells, through data transmitted
from the limbic forebrain and other structures transmit-
ted through the RVM, may dampen or amplify pain
impulses transmitted from the periphery.
56,59Activation
of the RVM off neurons or DLPT neurons via electrical
stimulation dampens activity of nociceptive neurons in
the dorsal horn.
56,58 These bidirectional on/off systems
determine vigilance to external threats as well as sensa-
tions coming from inside the body.
56,59 Decrease of sero-
tonin and/or norepinephrine neurotransmission as
occurs in depression may lead this descending system to
decrease its inhibitory effect so that nociceptive signals
from the body are considered stronger and more
salient.
59 This may explain the clinical experience of
patients with depression being quite focused on the
bothersomeness of many physical symptoms.
A recent systematic review of 31 studies found that
comorbid depression in patients with chronic medical ill-
nesses such as diabetes, congestive heart failure, CHD,
osteoarthritis, rheumatoid arthritis, asthma, or COPD was
associated with a significantly higher number of medical
symptoms after controlling for severity of medical ill-
ness.
21Across these medical conditions, depression was at
least as strongly associated with the number of medical
symptoms as were objective physiological measures.
21
Figure 2 shows the relationship of both comorbid depres-
sion and number of diabetes complications with a 10-
item diabetes symptom scale.
60 After controlling for
socioeconomic factors and severity of medical illness,
depression was more highly associated with each of these
10 symptoms than was the number of diabetes compli-
cations. 
Three randomized controlled studies that tested depres-
sion interventions in patients with a specific chronic
medical illness (COPD,
61 osteoarthritis,
62 or diabetes
63)
have also shown that, compared with controls, greater
improvement in comorbid depressive symptoms in
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intervention was associated with improvement in med-
ical symptoms without improvement in physiologic mea-
sures. For instance, Ell and colleagues tested a collabo-
rative care intervention versus usual care in 387 patients
with comorbid depression and diabetes. Compared with
usual primary care, collaborative care was associated
with improvements in quality of depression care, sever-
ity of depressive symptoms, and number of diabetes
symptoms, but lack of change in HbA1c levels.
63 Lin and
colleagues showed that a collaborative care intervention
that improved quality of depression care and depression
outcomes compared with usual primary care in over
1000 elderly patients with comorbid depression and pain
predominantly due to osteoarthritis was associated with
improvement in perception of pain intensity and
decreased pain interference during regular activities.
62
Risk of complications and mortality
Multiple large epidemiologic studies have examined
whether comorbid depression in patients with CHD or
diabetes increases risk of mortality. A recent meta-analy-
sis found 22 papers that examined the association of
depression with cardiovascular outcomes of patients
experiencing a recent myocardial infarction (MI),
defined as mortality or cardiovascular events occurring
within 2 years of index MI.
64 Comorbid depression was
associated with an approximate 2.4-fold increase in all-
cause mortality, a 2.6-fold increase in cardiovascular-
related mortality, and an almost 2.0-fold increase in new
cardiovascular events.
64 Depression has also been found
across multiple studies to be a significant predictor of
mortality and cardiac events in patients undergoing
coronary artery bypass surgery,
65-67 as well as those with
congestive heart failure.
68
Six prospective epidemiologic studies have shown that
after controlling for sociodemographic factors and clin-
ical severity of illness, comorbid depression in patients
with diabetes compared with those with diabetes alone
was associated with a 33% to 52% increase in risk of all-
cause mortality.
69-74 One recent study of over 4000
patients with diabetes examined specific causes of mor-
tality associated with depression documented with both
state mortality data and careful chart review. Comorbid
depression was associated with an approximately 50%
increase in risk of all-cause morbidity, and an over two-
fold risk of noncancer and nonatherosclerotic associated
mortality.
69
A large prospective study of an aging Hispanic popula-
tion found that both depression and diabetes were inde-
pendently associated with an increased risk of all-cause
mortality, and when combined they had a greater than
additive effect on mortality.
72 Thus, lifetime depression
was associated with a 1.64 (95% CI 1.17-2.28) and dia-
betes a 1.51 (95% CI 1.23, 1.86) hazard ratio for all-
cause mortality respectively, compared with those with-
out history of depression or diabetes.
72 Patients with
comorbid lifetime depression and diabetes had a hazard
ratio of 4.59 (95% CI 2.12, 9.93) of all-cause mortality
Depression and chronic medical illness - Katon Dialogues in Clinical Neuroscience - Vol 13 . No. 1 . 2011
13
Figure 2. Relationship of depression and diabetes complications to 10
diabetes symptoms. 
Reproduced from ref 60: Ludman EJ, Katon W, Russo J, et al.
Depression and diabetes symptom burden. Gen Hosp Psychiatry.
2004;26:430-436. Copyright © Elsevier 2004
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depression.
72 In another study that followed over 10 000
participants for 8 years, compared with those without
diabetes or depression, those with depression but no dia-
betes had a 1.20 (95% CI 1.03, 1.40) increase in all-cause
mortality, those with diabetes but no depression had a
1.88 (95% CI 1.55, 2.27) increase, and those with both
depression and diabetes a 2.50 (95% CI 2.04, 3.08)
increase in all-cause mortality.
73
In patients with diabetes, recent prospective studies have
examined the association of depression with subsequent
development of macrovascular and microvascular com-
plications. Lin and colleagues, in a prospective study of
over 4000 patients with diabetes found that comorbid
depression was associated with a 36% increased risk of
microvascular and 24% risk of macrovascular compli-
cations over a 5-year period.
74 A recent large study of
4000 patients with diabetes has also shown that comor-
bid depression in patients with diabetes was associated
with a twofold increased risk of development of foot
ulcers.
75 A second large study that included over half a
million Veterans with diabetes showed that comorbid
depression was associated with a 33% increased risk of
having a nontraumatic lower-limb amputation over a 4-
year period.
76 Black and colleagues found in the above-
described prospective study of aging Hispanic respon-
dents that having diabetes was associated with an
increased risk of 1.37 (95% CI 1.16, 1.62) for macrovas-
cular complications and 9.30 (95% CI 7.38, 11.15) for
microvascular complications compared with controls
without diabetes or depression.
72Those with depression
and diabetes had an increased risk compared with those
without history of diabetes or depression of 2.64 (95%
CI 1.73, 4.04) for macrovascular complications and 11.32
(95% CI 8.76, 15.43) for microvascular complications.
72
Both depression and diabetes have been found in mul-
tiple studies to be independent risk factors for develop-
ment of dementia.
77A recent study of over 4000 patients
with type 2 diabetes found that patients with comorbid
depression compared with those with diabetes alone had
a 2.7-fold increase in development of dementia over a 5-
year period.
78
Functional impairment
Interest in the adverse effect of depression on functional
impairment was stimulated by findings from the Medical
Outcomes survey. This large study showed that patients
with depression were at least as functionally impaired as
patients with chronic medical illnesses such as diabetes,
CHD, and arthritis.
22 Moreover, when depression was
comorbid with chronic physical illness, there was addi-
tive functional impairment.
22
One of the methodological challenges in assessing func-
tioning in patients with depression is whether reported
impairments result from true deficits or from reporting
bias. Methodologists have attempted to understand this
problem by comparing more “objective” impairment
such as length of time a patient walks on a stress tread-
mill test to more “subjective” functional measures.
Recent data have shown that depressed patients also
have significant deficits on these more “objective” mea-
sures. For instance, depressed patients whose cardiac
function is tested by stress treadmill EKG have been
found to be more likely to stop the test due to fatigue
prior to an adequate length of time for assessment.
79
Patients with depression with congestive heart failure
(CHF) also have been shown to have poorer perfor-
mance on the standard 6-minute walk compared with
those with CHF alone.
80
A recent study of over 4000 patients with diabetes has
shown that patients with comorbid depression and dia-
betes compared with those with diabetes alone had a 10-
fold increased risk of overall functional impairment as
well as low social function scores and a fourfold increase
in the risk of having 20 or more days of reduced house-
hold work in the last 30 days after controlling for med-
ical comorbidity.
81The number of diabetes complications
and the number of diabetes symptoms were also inde-
pendently associated with increased disability risks, but
had less impact compared with comorbid depression.
81
A second study examined the impact of depression in
1600 patients with diabetes who were still working part-
or full-time.
82 Depressive illness and diabetic symptoms
were associated with greater work disability, including
missing 5 or more days of work in the prior month and
severe difficulty performing work tasks.
82
Cross-sectional studies of patients with CHD and CHF
have also shown that comorbid depression is associated
with additive functional impairment.
83,84 Because it is
unclear whether decreased functioning causes depres-
sion or whether this affective illness leads to functional
decline, studies have begun to utilize longitudinal
designs. Longitudinal studies in aging populations have
described a bidirectional relationship between depres-
sion and functional impairment.
85-89 Functional impair-
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versely, major depression and depressive symptoms have
been found to be risk factors for progression of disabil-
ity.
85-88 Studies by Van Korff and colleagues
90 and Ormel
et al
91 have also shown that depressive symptoms and
disability measures change synchronously over time—
as depression improves, so do measures of functional
impairment. 
Prospective studies in both cardiology and primary
care settings have shown comorbid depression in
patients with CHF and CHD can be more predictive of
functional impairment over time than is severity of
physical illness. Sullivan and colleagues
80 showed that
in 113 patients with CHF in a specialty cardiology clinic
that comorbid depression was prospectively associated
with decreased distance on the 6-minute walk as well
as decreased self-reported functioning on generic and
disease-specific measures of function (Kansas City
Cardiomyopathy Questionnaire
92) after controlling for
demographic and clinical characteristics (such as left
ventricular ejection fraction). A primary care-based
study showed that over a 6-month period after con-
trolling for severity of cardiac disease, comorbid
depression in 139 patients with CHF was associated
with significant and persistent adverse effects on per-
ception of health, impairment on the Kansas City
Cardiomyopathy Questionnaire, physical limitations,
role function, and quality of life compared with patients
with CHF alone.
93 Depression was also shown to be the
strongest predictor of functional decline in a prospec-
tive study of patients with heart failure.
94
Sullivan and colleagues demonstrated that symptoms of
depression and anxiety at initial diagnosis of coronary
artery disease by angiogram were more highly corre-
lated with function impairment at both 1- and 5-year fol-
low-ups than was number of coronary occlusions.
95,96This
study controlled for the number of vessels occluded 70%
or more, ejection fraction at baseline, and cardiac pro-
cedures over time.
95,96 Mayou et al showed that in
patients with recent myocardial infarction, DSM-IV
depressive and anxiety disorders predicted poor out-
come at 1 year on all dimensions of quality of life.
97
Studies of patients with comorbid depression and dia-
betes,
63,98 coronary artery disease,
99 and those post-coro-
nary artery bypass surgery
100 have shown that enhancing
quality of care of depression not only improves depres-
sive outcomes but markedly improves functional out-
comes compared with control treatments.
Biological factors
Multiple biological links that potentially mediate the
adverse effect of comorbid depression on diabetes-
related and cardiovascular mortality have been
described. These include increased proinflammatory
cytokines, abnormalities of the hypothalamic pituitary
axis (HPA), changes in homeostasis between the sym-
pathetic and parasympathetic nervous systems and
changes in metabolism.
24,101As described in Figure 3, the
HPA axis and sympathetic nervous system are both acti-
vated by stress.
102The increased cortisol levels associated
with HPA activity and the increased catecholamine and
cytokine levels associated with increased sympathetic
activation may in turn lead to increased insulin resis-
tance, which is a risk factor for both diabetes and
CHD.
101,102
A recent meta-analysis found 24 studies that examined
links between major depression and cytokine levels.
Patients with depression were found to have significantly
higher concentrations of TNF-alpha (P<.00001) and
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Figure 3. Psychophysiologic effects of depression. HPA, hypothalamic-
pituitary-adrenal
Adapted from ref 102: Champaneri S, Wand GS, Malhotra SS,
Casagrande SS, Golden SH. Biological basis of depression in adults with
diabetes. Curr Diab Rep. 2010;10:396-405. Copyright © Current
Science 2010
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pressed subjects but no significant differences were found
in other cytokines that were examined.
103 Studies exam-
ining whether depression is associated with higher levels
of C-reactive protein have been inconsistent.
104,105
Depression may also increase the risk of cardiovascular
death through increased platelet aggregation.
106-108 A
recent study showed that mean plasma levels of factor 4
and β-thromboglobulin were higher in depressed patients
with ischemic heart disease than those with ischemic
heart disease alone or normal controls.
106 Other studies
have shown that patients with depression and stable
CHD compared with those with CHD alone have
increased β-thromboglobulin, fibrinogen, and d-dimer
levels.
107,108 Observational studies have also reported lower
stroke risk in patients with cardiovascular disease treated
with selective serotonin reuptake inhibitors (SSRIs,
which are known inhibitors of platelet activity).
109
Recent research has emphasized the importance of
endothelial dysfunction in patients with CHD which is
present even in preclinical stages of atherosclerosis.
24The
endothelium through the process of nitric oxide pro-
duction inhibits smooth muscle cell growth, platelet
aggregation, and leukocyte adhesion and maintains vas-
cular tone.
24 Depression has been linked in several stud-
ies to endothelial dysfunction.
110,111 Sherwood and col-
leagues showed that brachial flow-mediated dilation in
143 patients with CHD was impaired in patients report-
ing at least mild symptoms of depression.
110 Depression
has also been linked to higher levels of endothelin-1 in
patients with CHD.
111 Endothelin-1 has been found to be
associated with plaque rupture and post-acute coronary
syndrome survival.
111
Depression has been shown to be associated with ele-
vated 24-hour, urine-free cortisol levels, adrenal gland
enlargement and, in patients with severe depression, fail-
ure to suppress cortisol response to the dexamethasone
suppression test.
112 Researchers have recently posited
that in subjects with depression there is reduced respon-
siveness of the HPA axis to experimental and physiologic
challenges due to chronic hyperactivity of this endocrine
system.
102Thus, blunted cortisol response to acute mental
stressors has been shown in depressed compared with
nondepressed patients with multiple cardiovascular risk
factors.
113 Some,
114,115 but not all,
116 studies have shown flat-
ter diurnal cortisol profiles in individuals with depression.
Several studies have also shown an association of depres-
sion with impaired awakening cortisol levels.
117,118
A potential consequence of long-term activation of cor-
tisol is the development of central adiposity. Higher cor-
tisol levels may lead to redistribution of fat from subcu-
taneous to visceral fat depots.
119 Several studies have
shown that community respondents with depression had
an increased risk of higher amounts of visceral adipose
tissue (VAT).
120,121VAT promotes insulin resistance more
than subcutaneous fat, and is associated with a higher
risk of cardiovascular disease.
Depression is also associated with abnormalities in sym-
pathetic nervous system functioning, including decreased
heart rate variability (HRV), higher resting heart rates,
and higher heart rate responses to physical stres-
sors.
24,101,102 Increases in catecholamines and cytokines
associated with sympathetic hyperactivity may also lead
to insulin resistance and increases in blood pressure.
121,122
Low HRV has been linked to mortality in patients with
CHD and is a marker for excessive sympathetic and/or
decreased parasympathetic nervous system activity.
122,123
Most,
124,125 but not all,
126 studies have found depression to
be linked with decreased HRV in patients with coronary
disease. Other predictors of increased mortality and
autonomic nervous system dysfunction that have been
found in patients with comorbid depression and CHD
include increased heart rate response to orthostatic chal-
lenge,
127 increased QT interval variability reflecting
abnormal ventricular repolarization,
128 elevated resting
and 24-hour heart rates,
124,127 and abnormal heart rate
response to premature ventricular contractions.
129
Delayed heart rate recovery after the treadmill test is a
risk factor for cardiac mortality, and depression has been
linked to slower heart rate recovery.
130 This finding was
mediated by a reduced exercise capacity, which may
reflect the role of depression in leading to a more seden-
tary lifestyle. Depression in early adulthood has also
been linked in large population-based studies to
increased risk of development of hypertension.
11,131 Both
the increase in insulin resistance and hypertension typi-
cal of the metabolic syndrome may raise the risk of both
type 2 diabetes and CVD.
101,102 Moreover, hypertension
may lead to a higher risk of cerebrovascular disease
which can provoke vascular depression.
132
Insulin resistance is a risk factor for development of
both type 2 diabetes and cardiovascular disease.
101,102
Several large-scale, population-based studies have shown
that depression is associated with insulin resistance.
133
For instance, a Finnish 1966 birth cohort study that fol-
lowed young adult males over time found that males
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higher risk of insulin resistance. The Finnish findings
have been replicated in Chinese
134 and Dutch
135 samples
of similar age groups. On the other hand, a study of
Welsh males in midlife that were followed three times
over 14 years did not find a significant association
between insulin resistance and depression.
136 Thus, the
research in this area is promising but further large
prospective population-based studies are needed. 
Several longitudinal studies have examined whether the
effect of depression on mortality in patients with CHD
was mediated by psychophysiologic changes or health
risk behaviors associated with depression. Kop et al
showed that the increased mortality associated with
depression in 907 patients in the Cardiovascular Health
Study was partially mediated by autonomic dysfunction
(heart rate variability) and inflammatory factors (white
cell count, fibrinogen levels).
137 However, a large portion
of the predictive value of depression remained unex-
plained by these biological factors. A recent study of
1107 outpatients with stable coronary heart disease
found that depression was associated with a 31%
increased rate of cardiovascular events after controlling
for sociodemographic factors, comorbid conditions, and
cardiac disease severity.
138 Controlling for inflammatory
factors explained a small part of this increased risk;,
however, no significant relationship was found after
adjusting for physical activity and other health risk
behaviors.
138
Treatment of depression in patients
with diabetes and CHD
Large observational studies have found that the severity
of medical illness was a predictor of chronicity of depres-
sive symptoms in aging populations with medical illness.
4
Therefore, a key research question is whether evidence-
based psychotherapeutic and pharmacologic treatment
that are efficacious in depressed patients without chronic
medical illness are as effective in patients with depression
and comorbid illnesses such as diabetes and CHD. 
A recent meta-analysis of randomized trials of depres-
sion interventions in patients with diabetes and depres-
sion found five studies that tested the efficacy of psy-
chotherapy and seven that tested the efficacy of
antidepressant medications.
139 Four of the five psy-
chotherapy studies were quite small with 60 or fewer
patients, and all of the antidepressant trials had less than
90 patients. The meta-analysis showed both evidence
based depression psychotherapies and antidepressants
were efficacious in treating depression among patients
with diabetes with moderate to large effect sizes com-
pared with control treatments.
139
The meta-analysis also examined the results of three
large collaborative depression trials that provided a
choice of starting with antidepressants versus problem-
solving therapy (PST) and used stepped care principles
to increase intensity of depression treatment based on
lack of response to initial treatment.
63,98,140 In each trial, a
care manager supervised by a psychiatrist worked with
the primary care physician to enhance exposure to evi-
dence-based depression treatments. Thus, if the patient
chose PST and showed a lack of response an antide-
pressant medication could be added, and if they chose
medication and depressive symptoms did not improve,
either PST could be added, another medication could be
started, or a second antidepressant could be added as an
augmenting agent. These collaborative care trials
enrolled 329 to 417 patients each with few exclusion cri-
teria and in all three trials, collaborative care was more
effective in reducing depressive symptoms compared
with usual primary care.
63,98,140 Thus, collaborative care is
an effective health service model to improve exposure
to evidence-based depression care and depression out-
comes in large primary care populations with comorbid
depression and diabetes. 
In patients with comorbid depression and either CHD
or CHF there have been four large antidepressant tri-
als.
141-143The SADHEART trial randomized 369 patients
with major depression after acute MI to sertraline ver-
sus placebo.
141 Patients treated with sertraline had sig-
nificantly greater improvement on the Clinical Global
Impression (CGI) scale (67% vs 53% (P=.01) respon-
ders) but not on the Hamilton depression rating scale
(HAM-D) (P=.14). In the subsample of patients with a
history of recurrent major depression, both CGI and
HAM-D measures were significantly improved in those
assigned to sertraline versus placebo.
141 A Dutch trial
randomized 91 patients post-MI with comorbid major or
minor depression to mirtazapine versus placebo.
142 Using
the last observation carried forward, mirtazapine did not
show significance compared with placebo on the HAM-
D, but did on the Beck Depression Index, the SCL-20
depression scale, and CGI at 8 weeks.
142 Lesperance et al
randomized 224 patients with depression and CHD to
either citalopram versus placebo or interpersonal psy-
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agement alone.
99 Citalopram was superior to placebo in
reducing HAM-D scores and Beck depression scores.
However, interpersonal therapy and clinical manage-
ment was not significantly better than clinical manage-
ment alone.
99The SADHART-CHF (Sertraline Against
Depression and Heart Disease in Chronic Heart Failure
Trial) randomized 469 patients with comorbid major
depression and CHF to sertraline versus placebo.
Sertraline was not associated with greater efficacy com-
pared with placebo in improvement in depressive symp-
toms.
143 The effect sizes in the three trials that showed
efficacy of antidepressant medications compared with
placebo were relatively small, perhaps reflecting that
chronic disease problems limit the efficacy of antide-
pressant medications. Also, a subset of patients who
develop depressive symptoms post-myocardial infarc-
tion may actually have an adjustment reaction which
may improve with or without antidepressant treatment.
The finding in the SADHEART trial of a larger effect
size of sertraline versus placebo in those with recurrent
depression compared with those with a first depressive
episode occurring post-MI supports the premise that
many episodes of incident depression after MI may be
adjustment reactions.
141
The ENRICHD trial randomized 2481 post-MI patients
with minor or major depression to cognitive behavioral
therapy (CBT) versus usual medical care, with antide-
pressants also recommended for patients scoring higher
than 24 on the HAM-D or having less than a 50%
reduction on the Beck Depression Inventory after 5
weeks.
144 A significant effect was found on the HAM-D
in the intervention group that largely provided CBT
without medication compared with usual care. Freedland
and colleagues randomized 123 patients meeting DSM-
IV criteria for major or minor depression within 1 year
after coronary artery bypass surgery to CBT, supportive
stress management, or to usual care. Remission of
depression occurred in a higher proportion of patients
treated with CBT (71%) and supportive stress manage-
ment (57%) by 3 months compared with the usual care
group (33%) (P<0.002).
145 The CBT and supportive
stress management groups also had significantly lower
Hamilton depression scores than the usual care group at
3 months.
Two recent trials have tested whether collaborative
depression care is an effective health services model
compared with usual care to improve exposure to evi-
dence-based depression treatment in patients with car-
diac disease and comorbid depression.
100,146 Rollman et al
tested a telephone-delivered depression collaborative
care model provided by nurses working with patients’
primary care physicians and supervised by a psychiatrist
and primary care physician to enhance antidepressant
medication treatment and patient psychoeducation and
behavioral activation.
100 A total of 302 post-coronary
artery bypass graft patients with depression were ran-
domized to this intervention versus usual care.
Intervention versus usual care patients had significantly
greater improvement on mental health functioning
(P=0.02) and were more likely to report a >50% decline
on HAM-D scores (50% vs. 29.6%), P<0.001) at 8-
month follow-up compared with usual care patients.
100
Davidson and colleagues tested a depression collabora-
tive care model that gave patients a choice of starting
with pharmacotherapy or problem-solving therapy
(PST) to treat depression.
146 Stepped care was provided
based on physician supervision of case managers so that
medications could be added to PST if patients had lim-
ited response to psychotherapy or medications could be
changed, or PST added for patients not responding to
the initial antidepressant medication trial. A total of 157
patients with depression persistently present 3 months
after an acute coronary event were randomized and
intervention patients had significant improvements com-
pared with usual care patients on the Beck Depression
Inventory (P>0.005).
146
These two collaborative depression care trials, like the
three trials completed in patients with depression and
diabetes, demonstrate that this health services model is
an effective way to expose cardiac patients with depres-
sion to evidence-based depression treatments and to
improve depressive outcomes in large primary care pop-
ulations.
An important question raised by the epidemiologic data
is whether enhanced treatment of depression could lead
to decreased complications, and mortality in patients
with CHD or diabetes. With the exception of the
ENRICHD trial, all other trials are underpowered to
answer this important question. The small treatment
effect size in ENRICHD also limited the ability of
researchers to answer this question. Future trials with
as many as 5000 to 10 000 patients are likely needed
with enhanced quality control over the depression inter-
vention. However, regardless of the effect on complica-
tions and mortality, effective treatment of depression
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Conclusion
Depression is a risk factor for development of chronic
illnesses such as diabetes and CHD and adversely affects
the course, complications and management of chronic
medical illness. Both maladaptive health risk behaviors
and psychobiological factors associated with depression
may explain depression’s negative effect on outcomes of
chronic illness. Most treatment studies have found that
both evidence-based depression therapies and antide-
pressant medications are efficacious treatments in
patients with depression and comorbid medical illness,
and that collaborative care is an effective health services
model to deliver these treatments to large primary care
populations. ❏
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Epidemiología y tratamiento de la depresión
en pacientes con una enfermedad médica
crónica
Hay una relación bidireccional entre la depresión y
los trastornos médicos crónicos. Las conductas de
riesgo adversas para la salud y los cambios psico-
biológicos asociados con la depresión aumentan el
riesgo de trastornos médicos crónicos, y los cambios
biológicos y las complicaciones asociadas con los
trastornos médicos crónicos pueden precipitar epi-
sodios depresivos. La depresión comórbida está aso-
ciada con un aumento de las repercusiones de los
síntomas médicos, del deterioro funcional, de los
costos médicos, de una pobre adherencia a los regí-
menes de auto-cuidado, y un mayor riesgo de mor-
bilidad y mortalidad en los pacientes con trastornos
médicos crónicos. La depresión puede empeorar la
evolución de los trastornos médicos debido a su
efecto sobre los factores proinflamatorios, en el eje
hipotálamo-hipofisiario, en el sistema nervioso
autónomo y sobre los factores metabólicos, además
de estar asociada con un mayor riesgo de obesidad,
de un estilo de vida sedentario, de tabaquismo y de
una pobre adherencia a los tratamientos médicos.
Tanto las psicoterapias basadas en la evidencia
como los fármacos antidepresivos son tratamientos
eficaces para la depresión. Los modelos de atención
en salud de tipo colaborativo aplicados a la depre-
sión han demostrado ser una forma efectiva para
entregar estos tratamientos a grandes poblaciones
de pacientes en atención primaria con depresión y
enfermedades médicas crónicas.   
Épidémiologie et traitement de la 
dépression chez les patients ayant une 
pathologie chronique
La dépression et les pathologies chroniques sont
liées à double titre. Les comportements à risque
délétères pour la santé et les modifications psycho-
biologiques associés à la dépression augmentent le
risque de pathologies chroniques, tandis que les
complications et modifications biologiques asso-
ciées aux pathologies chroniques peuvent précipi-
ter des épisodes dépressifs. La dépression, chez les
patients présentant des pathologies chroniques, est
associée à une augmentation de la charge sympto-
matique, à une détérioration fonctionnelle, à des
coûts médicaux, à une mauvaise observance de l’au-
tosurveillance et à une augmentation du risque de
morbidité et de mortalité.. Elle peut aggraver le
cours des maladies à cause de ses effets sur les fac-
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manière collaborative est efficace pour soigner un
grand nombre de patients traités en soins primaires
atteints de dépression comorbide de pathologies
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